Atezolizumab/nivolumab/pembrolizumab
- PDF / 170,052 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 181 Views
1 S
Atezolizumab/nivolumab/pembrolizumab Autoimmune myocarditis, immune related myositis and immune related thyroiditis: 4 case reports
In a case series, four patients including 3 men and a woman aged 67–77 years were described, who developed autoimmune myocarditis, immune related myositis or immune related thyroiditis during treatment with atezolizumab, nivolumab or pembrolizumab for renal cell carcinoma or adenocarcinoma [dosages, routes and durations of treatments to reactions onsets not stated; not all outcomes stated]. Patient 1: A 67-year-old woman, who had been diagnosed with renal cell carcinoma, started receiving nivolumab. During the treatment, she developed autoimmune myocarditis diagnosed from abnormal myocardial tissue characteristics on CMRI and biopsy results. She also developed immune related myositis and thyroiditis. Her treatment management included high-dose unspecified steroids with immediate taper. Following combination of tiered treatment, she showed significant improvement in autoimmune myocarditis. Patient 2: A 76-year-old man, who had been diagnosed with bladder adenocarcinoma, started receiving pembrolizumab. During the treatment, he was diagnosed with autoimmune myocarditis from abnormal myocardial tissue characteristics on CMRI and biopsy results. He also developed immune related myositis. His treatment management included high-dose unspecified steroids and immediate taper. Following the combination of tiered treatment, he showed significant improvement in autoimmune myocarditis. Patient 3: A 77-year-old man, who had been diagnosed with renal cell carcinoma, started receiving atezolizumab. During the treatment, he was diagnosed with autoimmune myocarditis, based on abnormal myocardial tissue characteristics on CMRI and biopsy results. He also developed immune related myositis. His treatment management included high-dose unspecified steroids and immediate taper. Following the combination of tiered treatment, he had a significant improvement in autoimmune myocarditis. Patient 4: A 68-year-old man, who had been diagnosed with pancreatic adenocarcinoma, started receiving nivolumab. Thereafter, during the treatment, based on abnormal myocardial tissue characteristics on CMRI and biopsy results, he was diagnosed with autoimmune myocarditis. His subsequent treatment management included high-dose unspecified steroids with immediate taper. Following the combination of tiered treatment, he had a significant improvement in autoimmune myocarditis. Rao A, et al. Immune checkpoint inhibitioninduced myocarditis in cancer patients: Proposal of a detection and management strategy. Journal of Clinical Oncology 38: No. 15, 803503387 2020. Available from: URL: http://doi.org/10.1200/JCO.2020.38.15_suppl.e15116 [abstract]
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...